# A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

> **NCT03274817** · PHASE1 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 5 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Escitalopram Pill
- **DRUG:** Venlafaxine Pill
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03274817
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06-18
- **Primary completion:** 2019-09-25
- **Final completion:** 2019-09-25
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Insufficient Enrollment
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274817, "A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03274817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*